The European Medicines Agency has begun reviewing a new batch of drugs for potential pan-EU marketing approval, including resmetirom, Madrigal Pharmaceuticals’ THR-β agonist, which is awaiting a decision tomorrow on whether it will become the first approved treatment for non-alcoholic steatohepatitis (NASH) in the US.
Resmetirom is a once-daily, oral drug designed to target the key underlying causes of NASH, a potentially lucrative market that...








